Q4 Inc. and Diligent Partner to Deliver Best-In-Class Board Governance and Investor Relations Solutions to Pre-IPO and Public Companies
25.5.2022 16:00:00 EEST | Business Wire | Press release
Q4 Inc. (TSX: QFOR) (“Q4”), a leading capital markets communications platform provider, and Diligent, a global leader in modern governance providing SaaS solutions across governance, risk, compliance and ESG, today announced a partnership that will afford pre-IPO and public companies easy access to best-of-breed IR and board governance solutions, equipping them with the tools needed to achieve success at scale.
Through the partnership, listing companies will benefit from Diligent’s Board & Leadership Collaboration solution and Q4’s end-to-end Investor Relations platform in one easily accessible offering, allowing them to quickly implement market-leading solutions to fuel good governance and investor relations pre-IPO and beyond. Diligent’s end-to-end Board & Leadership Collaboration solution empowers and informs governance best practices for publicly traded companies across the fiscal year, from routine filings to preparing for an annual general meeting. Meanwhile, Q4’s Investor Relations platform integrates the critical tools needed to build a successful IR program, including a world-class CRM, AI targeting, capital market intelligence, and advanced analytics to drive improved investor engagement and deliver on strategic objectives.
“Given the public company mandate for effective governance in today’s environment, we are excited to broaden our marketplace of IR excellence with the inclusion of Diligent’s modern governance solutions,” said Q4’s CEO Darrell Heaps. “Q4 seeks to provide its clients direct access to a network of the top providers of products and services which are adjacent to Q4’s offerings, in effort to help our clients succeed as the capital markets evolve. We are thrilled to add Diligent to our growing list of partners in pursuit of this endeavor.”
"In this era of stakeholder capitalism, pre-IPO and publicly listed companies face more scrutiny than ever before. It’s important for leaders to have the tools to successfully navigate complex challenges to come out ahead,” said Ricardo Moreno, SVP of Worldwide Partnerships at Diligent. “As a leader in capital markets communications, Q4 was a natural partner for us in our mission to help leaders align their company practices with investor expectations.”
Working closely with more than 2,700 public companies and investment banks to discover, communicate and engage with the investment community, Q4 is always looking for opportunities to streamline and deliver innovative best practices across the capital markets. Diligent’s modern governance solutions enable one million users and more than 700,000 board members and leaders to connect insights across governance, risk, compliance, audit and ESG to drive greater impact and lead with purpose.
About Diligent:
Diligent is the global leader in modern governance, providing SaaS solutions across governance, risk, compliance and ESG. Serving more than 1 million users from over 25,000 customers around the world, we empower transformational leaders with technology, insights and confidence to drive greater impact and lead with purpose. Learn more at diligent.com.
About Q4 Inc.
Q4 Inc. (TSX: QFOR) is a leading capital markets communications platform that is transforming the way publicly traded companies, investors and investment banks make decisions to efficiently discover, communicate and engage with each other. The Q4 end-to-end technology platform facilitates interactions across the capital markets through its IR website products, virtual events solutions, capital markets CRM, shareholder and market analytics tools. The firm is a trusted partner to more than 2,700 public companies globally including many of the most respected brands in the world. Q4 is based in Toronto, with offices in New York and London. Learn more at q4inc.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220525005549/en/
Contact information
Investor inquiries: Sara Pearson, ir@q4inc.com
Media inquiries: Karen Greene, media@q4inc.com
Media Inquiries:
Julia Hanbury
Senior Communications Manager, Diligent
+1 778-822-6411
Jhanbury@diligent.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom